Ono strikes two deals as it shores up mid-stage pipeline
This article was originally published in Scrip
Executive Summary
Ono Pharmaceutical has acquired exclusive development and commercialisation rights in Japan to Servier's If channel agonist ivabradine and KAI Pharmaceuticals' secondary hyperparathyroidism therapy KAI-4169.